State Street Corp Xilio Therapeutics, Inc. Transaction History
State Street Corp
- $2.36 Trillion
- Q1 2025
A detailed history of State Street Corp transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 43,390 shares of XLO stock, worth $30,372. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,390
Previous 43,390
-0.0%
Holding current value
$30,372
Previous $41,000
24.39%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XLO
# of Institutions
34Shares Held
11.1MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.2 Million1.1% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.01 Million16.6% of portfolio
-
Morgan Stanley New York, NY1.16MShares$809,0860.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.14MShares$795,0010.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$467,4190.57% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $19.2M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...